FDA-cleared profile

OTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System

Perimeter Medical Imaging AI, Inc. · Optical Coherence Tomography · FDA-cleared (510(k))

Authorized purpose: OTIS 2.1 is indicated as an imaging tool for evaluating excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image-review manipulation software for identifying and annotating regions of interest.

Clinical role
OCT acquisition, real-time visualization, image manipulation, measurement, and annotation under professional control.
Images and patients
Optical Coherence Tomography · Excised human tissue microstructure
Key limitation
Keep in mind: The labeling is for evaluation of excised human tissue microstructure and image review or annotation; safety and effectiveness for diagnostic analysis of a specific abnormality or disease are not established by this statement.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: OTIS 2.1 is indicated as an imaging tool for evaluating excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image-review manipulation software for identifying and annotating regions of interest.
  • Which images or clinical context are in scope?Modality: Optical Coherence Tomography Anatomy or clinical context: Excised human tissue microstructure Input: OCT data from the supported imaging system, probe, tissue, and procedure configuration.
  • Who uses it?Intended users: Trained physicians and procedural or pathology professionals within the labeled tissue workflow.
  • What does the software produce?Output: Two-dimensional or volumetric cross-sectional OCT images, markers, annotations, and measurements for professional review.
  • What is its most important limitation?Key limitation: The labeling is for evaluation of excised human tissue microstructure and image review or annotation; safety and effectiveness for diagnostic analysis of a specific abnormality or disease are not established by this statement.

Clinical takeaway. Clinical role: OTIS 2.1 is indicated as an imaging tool for evaluating excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image-review manipulation software for identifying and annotating regions of interest.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports design verification and validation testing of OTIS 2.1 using the same test protocols/methodology as for OTIS 2.0, including biocompatibility testing of the consumable set and external laser, basic safety and electromagnetic compatibility testing; verification studies showed outputs met design input requirements and validation studies showed the device fulfilled the intended use and met user needs. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
OTIS 2.1 is indicated as an imaging tool for evaluating excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image-review manipulation software for identifying and annotating regions of interest.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
OCT acquisition, real-time visualization, image manipulation, measurement, and annotation under professional control.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
OCT data from the supported imaging system, probe, tissue, and procedure configuration.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Two-dimensional or volumetric cross-sectional OCT images, markers, annotations, and measurements for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical imaging or procedure settings within the labeled OCT workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained physicians and procedural or pathology professionals within the labeled tissue workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The labeling is for evaluation of excised human tissue microstructure and image review or annotation; safety and effectiveness for diagnostic analysis of a specific abnormality or disease are not established by this statement.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports design verification and validation testing of OTIS 2.1 using the same test protocols/methodology as for OTIS 2.0, including biocompatibility testing of the consumable set and external laser, basic safety and electromagnetic compatibility testing; verification studies showed outputs met design input requirements and validation studies showed the device fulfilled the intended use and met user needs. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "This ensured that verification studies demonstrated that outputs met design input requirements, and that validation studies demonstrated that the Perimeter OTIS™ 2.1 fulfilled the intended use and met user needs." … "Design verification and validation testing for OTIS 2.1 was carried out using the same test protocols/methodology as was used to test OTIS 2.0.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports design verification and validation testing of OTIS 2.1 using the same test protocols/methodology as for OTIS 2.0, including biocompatibility testing of the consumable set and external laser, basic safety and electromagnetic compatibility testing; verification studies showed outputs met design input requirements and validation studies showed the device fulfilled the intended use and met user needs. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "This ensured that verification studies demonstrated that outputs met design input requirements, and that validation studies demonstrated that the Perimeter OTIS™ 2.1 fulfilled the intended use and met user needs." … "Design verification and validation testing for OTIS 2.1 was carried out using the same test protocols/methodology as was used to test OTIS 2.0.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Lateral resolution

20 micrometers

  • EndpointOCT lateral resolution reported in the FDA comparison
  • PopulationExcised human tissue microstructure
  • Tested versionOTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System configuration described in K203578

Axial resolution midpoint

12.5 micrometers

  • EndpointMidpoint of the reported 10 to 15 micrometer axial-resolution range
  • PopulationExcised human tissue microstructure
  • Tested versionOTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System configuration described in K203578

K203578 FDA decision evidence package for OTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System

  • DesignFDA decision evidence including the exact submission's labeled performance or verification material; endpoints remain submission-specific.
  • PopulationExcised human tissue microstructure
  • Scopeexact submission
  • Tested versionOTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System configuration described in K203578
  • IndependenceSponsor or vendor study

K203578

FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K203578 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: OCT data from the supported imaging system, probe, tissue, and procedure configuration.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K203578: OTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Two-dimensional or volumetric cross-sectional OCT images, markers, annotations, and measurements for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K203578: OTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System

  5. Viewer/worklist/report

    Unresolved route: Two-dimensional or volumetric cross-sectional OCT images, markers, annotations, and measurements for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K203578: OTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Training
Only trained physicians and procedural or pathology professionals within the labeled tissue workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K203578 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The labeling is for evaluation of excised human tissue microstructure and image review or annotation; safety and effectiveness for diagnostic analysis of a specific abnormality or disease are not established by this statement.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K203578 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The labeling is for evaluation of excised human tissue microstructure and image review or annotation; safety and effectiveness for diagnostic analysis of a specific abnormality or disease are not established by this statement.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

exact submission · checked 2026-09-04

No exact-product price or reimbursement determination was promoted.

Lifecycle monitoring

Monitor K203578 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The labeling is for evaluation of excised human tissue microstructure and image review or annotation; safety and effectiveness for diagnostic analysis of a specific abnormality or disease are not established by this statement.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish a complete integration contract. Confirm supported inputs, outputs, identity, routing, archive behavior, audit behavior, and downtime locally.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

5 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K203578: OTIS 2.1 Optical Coherence Tomography System, THiA Optical Coherence Tomography System

    U.S. Food and Drug Administration - Published 2021-02-25 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K203578 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253459

OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)

ABBOTT MEDICAL

Authorized purpose: Abbott OPTIS Mobile or Integrated Next with Ultreon 3.0 processes compatible coronary intravascular OCT data to support visualization, measurement, and interventional assessment of coronary vessels.

Modality
Optical Coherence Tomography
Anatomy
Coronary arteries
Decision
2026-04-24
FDA-cleared K210458

OPTIS Mobile Next Imaging System, OPTIS Integrated Next Imaging System

Abbott Medical

Authorized purpose: OPTIS Mobile Next Imaging System and OPTIS Integrated Next Imaging System acquire, display, and analyze intravascular optical coherence tomography images for trained professionals in the labeled coronary and interventional workflow.

Modality
Optical Coherence Tomography
Anatomy
Coronary arteries and intravascular anatomy
Decision
2021-06-08
FDA-cleared K182616

NvisionVLE Imaging System, NvisionVLE Optical Probe, NvisionVLE Inflation System

NinePoint Medical, Inc.

Authorized purpose: The NvisionVLE Imaging System is an imaging tool for evaluating human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization and marking areas of tissue. The software provides segmentation and display of common imaging features including hyper-reflective surface, layering, and hypo-reflective structures. Safety and effectiveness for diagnostic analysis of normal versus a specific abnormality or disease have not been evaluated.

Modality
Optical Coherence Tomography
Anatomy
Human tissue microstructure, including esophageal tissue
Decision
2018-11-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history